Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- ALS and wildfire smoke remind me there’s only so much I can control
- Chinese study connects past smoking habits to increased risk for ALS
- Researcher honored for AI brain implant that helps restore speech in ALS
- Early ALS trial finds therapy well tolerated and lowers disease markers
- How new gene therapies are transforming genetic testing for ALS